• Cy3 TSA Fluorescence System Kit for IHC & ISH

  2026-09-15

  The Cy3 TSA Fluorescence System Kit extends conventional immunostaining into sensitive detection of low-abundance proteins, nucleic acids, and cell-surface signals. This practical guide connects tyramide signal amplification to intestinal barrier research, with workflow settings, assay controls, and troubleshooting strategies for reproducible fluorescence microscopy detection.

• Podocyte Exosomal HMGB1 in Lupus Nephritis

  2026-09-15

  The reference study identifies podocyte-derived exosomes carrying HMGB1 as a mechanistic link between podocyte activation and glomerular endothelial cell injury in lupus nephritis. Using pharmacologic, cargo-specific, genetic, and mouse-model experiments, it places TRIM27 downstream of exosomal HMGB1 and provides a framework for testing vesicle-mediated renal injury.

• ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors

  2026-09-14

  The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further suggest that ATRX status may help interpret RTK inhibitor responses alongside temozolomide treatment, although clinical validation and direct target-mechanism studies remain necessary.

• Gastrin I in Organoid-to-Assay Design

  2026-09-14

  Discover how Gastrin I and the human Gastrin I peptide can be used as a defined receptor-level perturbation across gastric acid secretion and intestinal organoid workflows. This article presents a compartment-aware framework for translating gastrointestinal physiology studies into reproducible pharmacokinetic and gastrointestinal disorder research assays.

• Triacetin: From Acetate Biology to Translation

  2026-09-13

  Triacetin, or glyceryl triacetate, sits at the intersection of acetate metabolism, epigenetic regulation, oncology, and formulation science. This thought-leadership analysis translates mechanistic findings into practical assay strategy while defining the evidence boundaries that researchers must address before pursuing therapeutic or clinical claims.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-12

  AZD8055 (SKU A8214) is a selective ATP-competitive mTOR inhibitor for preclinical studies requiring coordinated investigation of mTORC1 and mTORC2 signaling. It is best suited to controlled cellular, biochemical, and animal experiments, not to studies that require water-soluble dosing or direct clinical efficacy conclusions.

• (S)-(+)-Methoprene: Reliable JH Assays

  2026-09-11

  Learn how (S)-(+)-Methoprene (SKU C3249) can improve mechanistic interpretation of juvenile hormone, receptor-signaling, and cell-based assays. This scenario-driven guide connects product handling data with current evidence on miRNA-regulated juvenile hormone biosynthesis, while clarifying cross-species and cytotoxicity limitations.

• Ceftolozane Sulfate for PK/PD Research

  2026-09-11

  Ceftolozane sulfate supports mechanistic susceptibility testing, time-kill experiments, and translational PK/PD modeling against difficult Gram-negative pathogens. This guide connects practical assay design with resistance findings from Pseudomonas aeruginosa, while separating MIC-based screening from dynamic measurements of adaptive resistance.

• Relative vs Fractional Viability in Cancer Drug Testing

  2026-09-10

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of an in vitro cancer drug response. The framework supports better endpoint selection, time-course interpretation, and experimental designs that avoid labeling cytostatic effects as cytotoxicity.

• Pexidartinib: A Causal CSF1R Assay Framework

  2026-09-10

  Pexidartinib (PLX3397) enables a more precise test of how CSF1R-dependent myeloid cells shape tissue phenotypes. This article translates microglial seizure-susceptibility findings into a rigorous assay framework for cancer research and neuroimmune studies.

• Pazopanib (GW-786034) in ATRX Glioma Studies

  2026-09-09

  Build genotype-aware RTK experiments with Pazopanib (GW-786034), connecting ATRX status to viability, signaling, and angiogenesis readouts. This workflow combines concentration-controlled dosing, orthogonal validation, and TMZ combination testing for more interpretable cancer research.

• 7ACC2 and Lactate Flux: An Assay-First Guide

  2026-09-09

  7ACC2 is a monocarboxylate transporter 1 inhibitor that also perturbs mitochondrial pyruvate transport. This assay-first guide explains how to separate transport effects from broader immunometabolic hypotheses and design more interpretable cancer metabolism research.

• Clodronate Liposomes for Macrophage Studies

  2026-09-08

  Clodronate Liposomes provide a practical way to test whether macrophages causally shape tumor immunity, inflammation, or tissue repair in vivo. This guide connects macrophage depletion with orthogonal genetic and molecular assays, using colorectal cancer immunotherapy resistance as a model application.

• Annexin V-FITC/PI Apoptosis Assay Kit Guide

  2026-09-08

  The Annexin V-FITC/PI Apoptosis Assay Kit supports rapid separation of viable, early apoptotic, late apoptotic, and membrane-compromised cells using phosphatidylserine binding and PI uptake. It is suitable for research flow cytometry or fluorescence microscopy, but it should not be used alone to establish a specific death mechanism or for diagnostic or medical decisions.

• MLN8237 (Alisertib) Assay Workflows

  2026-09-07

  Build mechanism-focused Aurora A experiments with MLN8237 (Alisertib), from dose and timing pilots to mitotic, aneuploidy, and apoptosis readouts. The workflow combines cancer biology applications with a reference-informed strategy for separating kinase-driven chromosome missegregation from tubulin-mediated effects.

7974 records 1/532 page Next 12345 下5页 Last page